Ãœlo Langel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/529728/publications.pdf

Version: 2024-02-01

		6613	12946
360	21,935	79	131
papers	citations	h-index	g-index

372	372	372	15412
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cell-penetrating peptides. Trends in Pharmacological Sciences, 2000, 21, 99-103.	8.7	809
2	Cell-Penetrating Peptides: Design, Synthesis, and Applications. ACS Nano, 2014, 8, 1972-1994.	14.6	776
3	Mechanisms of Cellular Uptake of Cell-Penetrating Peptides. Journal of Biophysics, 2011, 2011, 1-10.	0.8	747
4	Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Advanced Drug Delivery Reviews, 2005, 57, 529-545.	13.7	732
5	Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nature Biotechnology, 1998, 16, 857-861.	17.5	570
6	Cell penetration by transportan. FASEB Journal, 1998, 12, 67-77.	0.5	444
7	Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Current Opinion in Pharmacology, 2006, 6, 509-514.	3.5	294
8	Delivery of short interfering RNA using endosomolytic cellâ€penetrating peptides. FASEB Journal, 2007, 21, 2664-2671.	0.5	293
9	Efficient Intracellular Delivery of Nucleic Acid Pharmaceuticals Using Cell-Penetrating Peptides. Accounts of Chemical Research, 2012, 45, 1132-1139.	15.6	272
10	Secondary structure of cell-penetrating peptides controls membrane interaction and insertion. Biochimica Et Biophysica Acta - Biomembranes, 2010, 1798, 1119-1128.	2.6	264
11	Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Research, 2011, 39, 3972-3987.	14.5	262
12	Cargo delivery kinetics of cell-penetrating peptides. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1515, 101-109.	2.6	256
13	VE-Cadherin-Derived Cell-Penetrating Peptide, pVEC, with Carrier Functions. Experimental Cell Research, 2001, 269, 237-244.	2.6	247
14	Deletion analogues of transportan. Biochimica Et Biophysica Acta - Biomembranes, 2000, 1467, 165-176.	2.6	244
15	Cell-penetrating peptides: A comparative membrane toxicity study. Analytical Biochemistry, 2005, 345, 55-65.	2.4	243
16	Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochemical Journal, 2007, 407, 285-292.	3.7	217
17	Cell-Penetrating Peptides: Mechanisms and Applications. Current Pharmaceutical Design, 2005, 11, 3597-3611.	1.9	216
18	Galanin and galanin antagonists: molecular and biochemical perspectives. Trends in Pharmacological Sciences, 1992, 13, 312-317.	8.7	209

#	Article	IF	Citations
19	Immunoprecipitation of mRNA-protein complexes. Nature Protocols, 2006, 1, 577-580.	12.0	204
20	PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Research, 2011, 39, 5284-5298.	14.5	199
21	A brief introduction to cell-penetrating peptides. Journal of Molecular Recognition, 2003, 16, 227-233.	2.1	188
22	The use of cell-penetrating peptides as a tool for gene regulation. Drug Discovery Today, 2004, 9, 395-402.	6.4	185
23	Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochemical Pharmacology, 2006, 71, 416-425.	4.4	183
24	Protein Cargo Delivery Properties of Cell-Penetrating Peptides. A Comparative Study. Bioconjugate Chemistry, 2004, 15, 1246-1253.	3.6	181
25	Galanin Modulation of Seizures and Seizure Modulation of Hippocampal Galanin in Animal Models of Status Epilepticus. Journal of Neuroscience, 1998, 18, 10070-10077.	3.6	172
26	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nature Genetics, 2018, 50, 979-989.	21.4	168
27	Cellular translocation of proteins by transportan. FASEB Journal, 2001, 15, 1451-1453.	0.5	163
28	A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. Journal of Controlled Release, 2009, 134, 221-227.	9.9	163
29	Mechanism of the Cell-Penetrating Peptide Transportan 10 Permeation of Lipid Bilayers. Biophysical Journal, 2007, 92, 2434-2444.	0.5	161
30	Distinct Uptake Routes of Cell-Penetrating Peptide Conjugates. Bioconjugate Chemistry, 2008, 19, 2535-2542.	3.6	159
31	A Novel Cell-penetrating Peptide, M918, for Efficient Delivery of Proteins and Peptide Nucleic Acids. Molecular Therapy, 2007, 15, 1820-1826.	8.2	148
32	Galanin reduces release of endogeneous excitatory amino acids in the rat hippocampus. European Journal of Pharmacology, 1993, 245, 1-7.	2.6	145
33	Predicting cell-penetrating peptides. Advanced Drug Delivery Reviews, 2008, 60, 572-579.	13.7	140
34	Cell-penetrating peptidesâ€"A brief introduction. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 260-263.	2.6	138
35	Interaction and structure induction of cell-penetrating peptides in the presence of phospholipid vesicles. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1512, 77-89.	2.6	137
36	Molecular Parameters of siRNAâ€"Cell Penetrating Peptide Nanocomplexes for Efficient Cellular Delivery. ACS Nano, 2013, 7, 3797-3807.	14.6	135

#	Article	IF	Citations
37	Cell entry and antimicrobial properties of eukaryotic cellâ€•penetrating peptides. FASEB Journal, 2004, 18, 1-15.	0.5	127
38	In vivo biodistribution and efficacy of peptide mediated delivery. Trends in Pharmacological Sciences, 2010, 31, 528-535.	8.7	127
39	Scavenger receptorâ€mediated uptake of cellâ€penetrating peptide nanocomplexes with oligonucleotides. FASEB Journal, 2012, 26, 1172-1180.	0.5	127
40	Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7136-7141.	7.1	125
41	Cell-penetrating peptides for the delivery of nucleic acids. Expert Opinion on Drug Delivery, 2012, 9, 823-836.	5.0	125
42	In vitro Uptake and Stability Study of pVEC and Its All-D Analog. Biological Chemistry, 2003, 384, 387-93.	2.5	124
43	Design of a Tumor-Homing Cell-Penetrating Peptide. Bioconjugate Chemistry, 2008, 19, 70-75.	3.6	124
44	Induction of splice correction by cell-penetrating peptide nucleic acids. Journal of Gene Medicine, 2006, 8, 1262-1273.	2.8	120
45	Sensitive and Rapid Detection of Chlamydia trachomatis by Recombinase Polymerase Amplification Directly from Urine Samples. Journal of Molecular Diagnostics, 2014, 16, 127-135.	2.8	120
46	Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrenebutyrate. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 2509-2517.	2.6	119
47	Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochemical Journal, 2004, 377, 69-76.	3.7	118
48	Galanin Receptors and Ligands. Frontiers in Endocrinology, 2012, 3, 146.	3.5	116
49	Applications of Cell-Penetrating Peptides for Tumor Targeting and Future Cancer Therapies. Pharmaceuticals, 2012, 5, 991-1007.	3.8	115
50	Recentin vivoadvances in cell-penetrating peptide-assisted drug delivery. Expert Opinion on Drug Delivery, 2016, 13, 373-387.	5.0	115
51	Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. Journal of Controlled Release, 2010, 141, 42-51.	9.9	113
52	Classes and Prediction of Cell-Penetrating Peptides. Methods in Molecular Biology, 2011, 683, 3-19.	0.9	113
53	PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo. Journal of Controlled Release, 2015, 209, 238-247.	9.9	110
54	Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. European Journal of Neuroscience, 2004, 19, 3235-3244.	2.6	105

#	Article	IF	Citations
55	Novel cellâ€penetrating peptide targeting mitochondria. FASEB Journal, 2015, 29, 4589-4599.	0.5	105
56	Galanin receptor and its ligands in the rat hippocampus. FEBS Journal, 1989, 181, 269-276.	0.2	103
57	CXCR4 Stimulates Macropinocytosis: Implications for Cellular Uptake of Arginine-Rich Cell-Penetrating Peptides and HIV. Chemistry and Biology, 2012, 19, 1437-1446.	6.0	103
58	Secondary Structure and Position of the Cell-Penetrating Peptide Transportan in SDS Micelles As Determined by NMR. Biochemistry, 2001, 40, 3141-3149.	2.5	102
59	Characterization of a Novel Cytotoxic Cellâ€penetrating Peptide Derived From p14ARF Protein. Molecular Therapy, 2008, 16, 115-123.	8.2	99
60	Knockdown of L Calcium Channel Subtypes: Differential Effects in Neuropathic Pain. Journal of Neuroscience, 2010, 30, 1073-1085.	3.6	97
61	Differential Role of Galanin Receptors in the Regulation of Depression-Like Behavior and Monoamine/Stress-Related Genes at the Cell Body Level. Neuropsychopharmacology, 2008, 33, 2573-2585.	5.4	94
62	Galanin and Its Receptors in Neurological Disorders. NeuroMolecular Medicine, 2005, 7, 157-180.	3.4	92
63	Design of chimeric peptide ligands to galanin receptors and substance P receptors. International Journal of Peptide and Protein Research, 1992, 39, 516-522.	0.1	92
64	Cell-Penetrating Peptides, PepFects, Show No Evidence of Toxicity and Immunogenicity In Vitro and In Vivo. Bioconjugate Chemistry, 2011, 22, 2255-2262.	3.6	91
65	Penetration without cells: Membrane translocation of cell-penetrating peptides in the model giant plasma membrane vesicles. Journal of Controlled Release, 2011, 153, 117-125.	9.9	89
66	Regulation of Kindling Epileptogenesis by Hippocampal Galanin Type 1 and Type 2 Receptors: The Effects of Subtype-Selective Agonists and the Role of G-Protein-Mediated Signaling. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 700-708.	2.5	88
67	N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis. Biochemical and Biophysical Research Communications, 2006, 348, 379-385.	2.1	88
68	The novel high-affinity antagonist, galantide, blocks the galanin-mediated inhibition of glucose-induced insulin secretion. European Journal of Pharmacology, 1992, 210, 183-188.	3.5	86
69	Galaninâ€"A neuropeptide with inhibitory actions. Cellular and Molecular Neurobiology, 1995, 15, 653-673.	3.3	86
70	Prediction of Cell-Penetrating Peptides. International Journal of Peptide Research and Therapeutics, 2005, 11, 249-259.	1.9	86
71	In vivo identification of ribonucleoprotein-RNA interactions. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1557-1562.	7.1	86
72	Galanin receptor subtypes and ligand binding. Neuropeptides, 2000, 34, 331-337.	2.2	85

#	Article	IF	Citations
73	Structureâ€“activity relationship study of the cell-penetrating peptide pVEC. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 721-729.	2.6	85
74	Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling. Toxicology, 2009, 265, 87-95.	4.2	85
75	Gene delivery using cell penetrating peptides-zeolitic imidazolate frameworks. Microporous and Mesoporous Materials, 2020, 300, 110173.	4.4	85
76	Translocation Properties of Novel Cell Penetrating Transportan and Penetratin Analogues. Bioconjugate Chemistry, 2000, 11, 619-626.	3.6	84
77	Therapeutic potential of cell-penetrating peptides. Therapeutic Delivery, 2013, 4, 573-591.	2.2	84
78	PepFect14 Peptide Vector for Efficient Gene Delivery in Cell Cultures. Molecular Pharmaceutics, 2013, 10, 199-210.	4.6	83
79	The neuropeptide galanin modulates behavioral and neurochemical signs of opiate withdrawal. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9028-9033.	7.1	82
80	Cell-penetrating peptides with intracellular organelle targeting. Expert Opinion on Drug Delivery, 2017, 14, 245-255.	5.0	81
81	The role of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating peptides. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 502-511.	2.6	80
82	New generation of efficient peptide-based vectors, NickFects, for the delivery of nucleic acids. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 1365-1373.	2.6	78
83	Graphene oxide nanosheets in complex with cell penetrating peptides for oligonucleotides delivery. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2334-2341.	2.4	77
84	Cell Transduction Pathways of Transportans. Bioconjugate Chemistry, 2005, 16, 1399-1410.	3.6	76
85	Different domains in the third intracellular loop of the GLP-1 receptor are responsible for GÎ±s and GÎ±i/GÎ±o activation. BBA - Proteins and Proteomics, 2001, 1546, 79-86.	2.1	75
86	Carbonized chitosan encapsulated hierarchical porous zeolitic imidazolate frameworks nanoparticles for gene delivery. Microporous and Mesoporous Materials, 2020, 302, 110200.	4.4	74
87	Evaluation of transportan 10 in PEI mediated plasmid delivery assay. Journal of Controlled Release, 2005, 103, 511-523.	9.9	72
88	Magnetic Nanoparticle Assisted Self-assembly of Cell Penetrating Peptides-Oligonucleotides Complexes for Gene Delivery. Scientific Reports, 2017, 7, 9159.	3.3	71
89	PNA oligomers as tools for specific modulation of gene expression. New Biotechnology, 2001, 17, 183-192.	2.7	70
90	Differential membrane perturbation caused by the cell penetrating peptide Tp10 depending on attached cargo. FEBS Letters, 2007, 581, 2389-2393.	2.8	70

#	Article	IF	Citations
91	Uptake Mechanism of Cell-Penetrating Peptides. Advances in Experimental Medicine and Biology, 2017, 1030, 255-264.	1.6	70
92	Chitosan enhances gene delivery of oligonucleotide complexes with magnetic nanoparticlesâ€“cell-penetrating peptide. Journal of Biomaterials Applications, 2018, 33, 392-401.	2.4	70
93	Translocation of Dynorphin Neuropeptides across the Plasma Membrane. Journal of Biological Chemistry, 2005, 280, 26360-26370.	3.4	68
94	Translocation of cell-penetrating peptides across the plasma membrane is controlled by cholesterol and microenvironment created by membranous proteins. Journal of Controlled Release, 2014, 192, 103-113.	9.9	67
95	Differences in DNA Condensation and Release by Lysine and Arginine Homopeptides Govern Their DNA Delivery Efficiencies. Molecular Pharmaceutics, 2011, 8, 1729-1741.	4.6	66
96	The future of peptides in cancer treatment. Current Opinion in Pharmacology, 2019, 47, 27-32.	3.5	66
97	TP10, a delivery vector for decoy oligonucleotides targeting the Myc protein. Journal of Controlled Release, 2005, 110, 189-201.	9.9	64
98	Studying the uptake of cell-penetrating peptides. Nature Protocols, 2006, 1, 1001-1005.	12.0	64
99	Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay. Biochimica Et Biophysica Acta - Biomembranes, 2010, 1798, 338-343.	2.6	64
100	Galanin Acts at GalR1 Receptors in Spinal Antinociception: Synergy with Morphine and AP-5. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 574-582.	2.5	63
101	Design of a Tumor Homing Cell-Penetrating Peptide for Drug Delivery. International Journal of Peptide Research and Therapeutics, 2009, 15, 11-15.	1.9	58
102	Cell-penetrating peptides for siRNA delivery to glioblastomas. Peptides, 2018, 104, 62-69.	2.4	58
103	Chemically modified cell-penetrating peptides for the delivery of nucleic acids. Expert Opinion on Drug Delivery, 2009, 6, 1195-1205.	5.0	56
104	Impairment of GABAB receptor dimer by endogenous 14-3-3Î¶ in chronic pain conditions. EMBO Journal, 2012, 31, 3239-3251.	7.8	56
105	Optimization of in vivo DNA delivery with NickFect peptide vectors. Journal of Controlled Release, 2016, 241, 135-143.	9.9	56
106	Status update in the use of cell-penetrating peptides for the delivery of macromolecular therapeutics. Expert Opinion on Biological Therapy, 2021, 21, 361-370.	3.1	56
107	Cell-penetrating peptides in protein mimicry and cancer therapeutics. Advanced Drug Delivery Reviews, 2022, 180, 114044.	13.7	55
108	Protein Delivery with Transportans Is Mediated by Caveolae Rather Than Flotillin-Dependent Pathways. Bioconjugate Chemistry, 2009, 20, 877-887.	3.6	54

#	ARTICLE	IF	CITATIONS
109	Novel Target for Peptide-Based Imaging and Treatment of Brain Tumors. Molecular Cancer Therapeutics, 2014, 13, 996-1007.	4.1	54
110	Assessing the delivery efficacy and internalization route of cell-penetrating peptides. Nature Protocols, 2007, 2, 2043-2047.	12.0	53
111	Classes of Cell-Penetrating Peptides. Methods in Molecular Biology, 2015, 1324, 3-28.	0.9	53
112	Apolar surface area determines the efficiency of translocon-mediated membrane-protein integration into the endoplasmic reticulum. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E359-E364.	7.1	52
113	Differential Endosomal Pathways for Radically Modified Peptide Vectors. Bioconjugate Chemistry, 2013, 24, 1721-1732.	3.6	52
114	Killer Bee Molecules: Antimicrobial Peptides as Effector Molecules to Target Sporogonic Stages of Plasmodium. PLoS Pathogens, 2013, 9, e1003790.	4.7	52
115	Cellular Internalization of a Cargo Complex with a Novel Peptide Derived from the Third Helix of the Islet-1 Homeodomain. Comparison with the Penetratin Peptide. Bioconjugate Chemistry, 2001, 12, 911-916.	3.6	51
116	Characterization of Bioactive Cell Penetrating Peptides from Human Cytochrome c: Protein Mimicry and the Development of a Novel Apoptogenic Agent. Chemistry and Biology, 2010, 17, 735-744.	6.0	51
117	NickFects, Phosphorylated Derivatives of Transportan 10 for Cellular Delivery of Oligonucleotides. International Journal of Peptide Research and Therapeutics, 2011, 17, 147-157.	1.9	51
118	Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. Journal of Controlled Release, 2012, 162, 1-8.	9.9	51
119	Fluorescence Correlation Spectroscopy Detects Galanin Receptor Diversity on Insulinoma Cells. Biochemistry, 2001, 40, 10839-10845.	2.5	50
120	Galanin receptor ligands. Neuropeptides, 2005, 39, 143-146.	2.2	50
121	Galanin Protects Against Behavioral and Neurochemical Correlates of Opiate Reward. Neuropsychopharmacology, 2008, 33, 1864-1873.	5.4	50
122	CPPâ€“protein constructs induce a population of non-acidic vesicles during trafficking through endo-lysosomal pathway. Journal of Controlled Release, 2009, 139, 108-117.	9.9	50
123	Organellar oligopeptidase (OOP) provides a complementary pathway for targeting peptide degradation in mitochondria and chloroplasts. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E3761-9.	7.1	50
124	Overexpression of Protein-Tyrosine Phosphatase PTPÏƒ Is Linked to Impaired Glucose-Induced Insulin Secretion in Hereditary Diabetic Goto-Kakizaki Rats. Biochemical and Biophysical Research Communications, 2002, 291, 945-950.	2.1	49
125	Internalisation of cell-penetrating peptides into tobacco protoplasts. Biochimica Et Biophysica Acta - Biomembranes, 2005, 1669, 101-107.	2.6	49
126	Applications of cell-penetrating peptides in regulation of gene expression. Biochemical Society Transactions, 2007, 35, 770-774.	3.4	49

#	Article	IF	Citations
127	Prediction of Cell-Penetrating Peptides Using Artificial Neural Networks. Current Computer-Aided Drug Design, 2010, 6, 79-89.	1.2	49
128	Cell-Penetrating Peptide TP10 Shows Broad-Spectrum Activity against both Plasmodium falciparum and Trypanosoma brucei brucei. Antimicrobial Agents and Chemotherapy, 2008, 52, 3414-3417.	3.2	48
129	A galanin-mastoparan chimeric peptide activates the Na+,K+-ATPase and reverses its inhibition by ouabain. Regulatory Peptides, 1996, 62, 47-52.	1.9	47
130	Cav1.2 and Cav1.3 Lâ€type calcium channels independently control shortâ€and longâ€term sensitization to pain. Journal of Physiology, 2016, 594, 6607-6626.	2.9	47
131	Saturated Fatty Acid Analogues of Cell-Penetrating Peptide PepFect14: Role of Fatty Acid Modification in Complexation and Delivery of Splice-Correcting Oligonucleotides. Bioconjugate Chemistry, 2017, 28, 782-792.	3.6	47
132	A Galanin Receptor Subtype 1 Specific Agonist. International Journal of Peptide Research and Therapeutics, 2005, 11, 17-27.	1.9	46
133	c-Jun Supports Ribosomal RNA Processing and Nucleolar Localization of RNA Helicase DDX21. Journal of Biological Chemistry, 2008, 283, 7046-7053.	3.4	46
134	PepFect15, a novel endosomolytic cell-penetrating peptide for oligonucleotide delivery via scavenger receptors. International Journal of Pharmaceutics, 2013, 441, 242-247.	5.2	46
135	Galanin message-associated peptide (GMAP)- and galanin-like immunoreactivities: Overlapping and differential distributions in the rat. Neuroscience Letters, 1992, 142, 139-142.	2.1	44
136	p53 Latency. Journal of Biological Chemistry, 2001, 276, 15650-15658.	3.4	44
137	Characteristics of Cell-Penetrating Peptide/Nucleic Acid Nanoparticles. Molecular Pharmaceutics, 2016, 13, 172-179.	4.6	44
138	Differential effects of the putative galanin receptor antagonists M15 and M35 on striatal acetylcholine release. European Journal of Pharmacology, 1993, 242, 59-64.	3.5	43
139	Uptake of cell-penetrating peptides in yeasts. FEBS Letters, 2005, 579, 5217-5222.	2.8	43
140	New high affinity peptide antagonists to the spinal galanin receptor. British Journal of Pharmacology, 1995, 116, 2076-2080.	5.4	42
141	Cellular Internalization Kinetics of (Luciferin-)Cell-Penetrating Peptide Conjugates. Bioconjugate Chemistry, 2010, 21, 1662-1672.	3.6	42
142	Peptide-Based Glioma-Targeted Drug Delivery Vector gHoPe2. Bioconjugate Chemistry, 2013, 24, 305-313.	3.6	42
143	Pre-administration of PepFect6-microRNA-146a nanocomplexes inhibits inflammatory responses in keratinocytes and in a mouse model of irritant contact dermatitis. Journal of Controlled Release, 2016, 235, 195-204.	9.9	42
144	Binding and agonist/antagonist actions of M35, galanin(1-13)-bradykinin(2-9) amide chimeric peptide, in Rin m 5F insulinoma cells. Regulatory Peptides, 1995, 59, 341-348.	1.9	41

#	Article	IF	Citations
145	Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling. Regulatory Peptides, 2003, 111, 137-144.	1.9	41
146	Protein Delivery by the Cell-Penetrating Peptide YTA2. Bioconjugate Chemistry, 2007, 18, 170-174.	3.6	41
147	The Formation of Nanoparticles between Small Interfering RNA and Amphipathic Cell-Penetrating Peptides. Molecular Therapy - Nucleic Acids, 2017, 7, 1-10.	5.1	41
148	Recent CPP-based applications in medicine. Expert Opinion on Drug Delivery, 2019, 16, 1183-1191.	5.0	41
149	A novel GalR2-specific peptide agonist. Neuropeptides, 2009, 43, 187-192.	2.2	40
150	Intracellular translocation and differential accumulation of cell-penetrating peptides in bovine spermatozoa: evaluation of efficient delivery vectors that do not compromise human sperm motility. Human Reproduction, 2013, 28, 1874-1889.	0.9	40
151	Cell-penetrating Peptides Split into Two Groups Based on Modulation of Intracellular Calcium Concentration. Journal of Biological Chemistry, 2012, 287, 16880-16889.	3.4	39
152	Modeling the endosomal escape of cell-penetrating peptides using a transmembrane pH gradient. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 1198-1204.	2.6	39
153	Effective in vivo gene delivery with reduced toxicity, achieved by charge and fatty acid -modified cell penetrating peptide. Scientific Reports, 2017, 7, 17056.	3.3	39
154	Co-localized neuropeptide Y and GABA have complementary presynaptic effects on sensory synaptic transmission. European Journal of Neuroscience, 1998, 10, 2856-2870.	2.6	38
155	A protocol for PAIR: PNA-assisted identification of RNA binding proteins in living cells. Nature Protocols, 2006, 1, 920-927.	12.0	38
156	Intrathecal administration of PNA targeting galanin receptor reduces galanin-mediated inhibitory effect in the rat spinal cord. NeuroReport, 2001, 12, 317-320.	1.2	37
157	Âµâ€Opioid receptor activation in live cells. FASEB Journal, 2008, 22, 3537-3548.	0.5	37
158	Biochemical mechanisms of calcium mobilisation induced by mastoparan and chimeric hormonewmastoparan constructs. Cell Calcium, 1998, 24, 27-34.	2.4	36
159	Influence of stearyl and trifluoromethylquinoline modifications of the cell penetrating peptide TP10 on its interaction with a lipid membrane. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 915-924.	2.6	36
160	pH-responsive PepFect cell-penetrating peptides. International Journal of Pharmaceutics, 2016, 501, 32-38.	5.2	36
161	Enhancement of siRNA transfection by the optimization of fatty acid length and histidine content in the CPP. Biomaterials Science, 2019, 7, 4363-4374.	5.4	36
162	Isolation and characterization of galanin from sheep brain. Peptides, 1991, 12, 855-859.	2.4	35

#	Article	IF	Citations
163	Chimeric strategies for the rational design of bioactive analogs of small peptide hormones. FASEB Journal, 1997, 11, 582-591.	0.5	35
164	Design, synthesis and properties of novel powerful antioxidants, glutathione analogues. Free Radical Research, 2007, 41, 779-787.	3.3	35
165	Antiprion properties of prion proteinâ€derived cellâ€penetrating peptides. FASEB Journal, 2008, 22, 2177-2184.	0.5	35
166	Novel galanin receptor subtype specific ligands in feeding regulation. Neurochemistry International, 2011, 58, 714-720.	3.8	35
167	Novel systemically active galanin receptor 2 ligands in depressionâ€like behavior. Journal of Neurochemistry, 2013, 127, 114-123.	3.9	35
168	A convergent uptake route for peptide- and polymer-based nucleotide delivery systems. Journal of Controlled Release, 2015, 206, 58-66.	9.9	35
169	Structural determinants for binding to CGRP receptors expressed by human SK-N-MC and Col 29 cells: studies with chimeric and other peptides. British Journal of Pharmacology, 1998, 124, 1659-1666.	5.4	34
170	Bioportide: an emergent concept of bioactive cell-penetrating peptides. Cellular and Molecular Life Sciences, 2012, 69, 2951-2966.	5.4	34
171	The Antimicrobial and Antiviral Applications of Cell-Penetrating Peptides. Methods in Molecular Biology, 2015, 1324, 223-245.	0.9	34
172	Selective stimulation of GalR1 and GalR2 in rat substantia gelatinosa reveals a cellular basis for the anti- and pro-nociceptive actions of galanin. Pain, 2008, 137, 138-146.	4.2	33
173	Role of scavenger receptors in peptide-based delivery of plasmid DNA across a bloodâ€“brain barrier model. International Journal of Pharmaceutics, 2016, 500, 128-135.	5.2	33
174	Galanin receptors from human pituitary tumors assayed with human galanin as ligand. Brain Research, 1993, 625, 173-176.	2.2	32
175	NickFect type of cell-penetrating peptides present enhanced efficiency for microRNA-146a delivery into dendritic cells and during skin inflammation. Biomaterials, 2020, 262, 120316.	11.4	32
176	Chemistry and Molecular Biology of Galanin Receptor Ligands a. Annals of the New York Academy of Sciences, 1998, 863, 86-93.	3.8	31
177	NMR Study of the Conformation and Localization of Porcine Galanin in SDS Micelles. Comparison with an Inactive Analog and a Galanin Receptor Antagonistâ€. Biochemistry, 1998, 37, 9169-9178.	2.5	31
178	Splice-switching efficiency and specificity for oligonucleotides with locked nucleic acid monomers. Biochemical Journal, 2008, 412, 307-313.	3.7	31
179	PepFects and NickFects for the Intracellular Delivery of Nucleic Acids. Methods in Molecular Biology, 2015, 1324, 303-315.	0.9	31
180	Mutagenesis and Ligand Modification Studies on Galanin Binding to its GTP-Binding-Protein-Coupled Receptor GalR1. FEBS Journal, 1997, 249, 601-606.	0.2	30

#	Article	IF	Citations
181	Intracerebroventricular administration of galanin or galanin receptor subtype 1 agonist M617 induces c-Fos activation in central amygdala and dorsomedial hypothalamus. Peptides, 2007, 28, 1120-1124.	2.4	30
182	GalR3 activation promotes adult neural stem cell survival in response to a diabetic milieu. Journal of Neurochemistry, 2013, 127, 209-220.	3.9	30
183	Rational design of a series of novel amphipathic cell-penetrating peptides. International Journal of Pharmaceutics, 2014, 464, 111-116.	5.2	30
184	Cellâ€penetrating peptides recruit type A scavenger receptors to the plasma membrane for cellular delivery of nucleic acids. FASEB Journal, 2017, 31, 975-988.	0.5	30
185	Multiple interaction sites of galnon trigger its biological effects. Neuropeptides, 2005, 39, 547-558.	2.2	29
186	Novel galanin receptor ligands. Chemical Biology and Drug Design, 1998, 51, 65-74.	1.1	29
187	Retro-inversion of certain cell-penetrating peptides causes severe cellular toxicity. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 1544-1551.	2.6	29
188	CPP, Cell-Penetrating Peptides. , 2019, , .		29
189	Assay for Galanin Receptor. Methods in Neurosciences, 1991, , 225-234.	0.5	29
190	Systemic galnon, a low-molecular weight galanin receptor agonist, reduces heat hyperalgesia in rats with nerve injury. European Journal of Pharmacology, 2003, 482, 133-137.	3.5	28
191	Porous Siliconâ€“Cell Penetrating Peptide Hybrid Nanocarrier for Intracellular Delivery of Oligonucleotides. Molecular Pharmaceutics, 2014, 11, 382-390.	4.6	28
192	Effects of cargo molecules on membrane perturbation caused by transportan10 based cell-penetrating peptides. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 3118-3129.	2.6	28
193	Blockade of galanin-induced inhibition of insulin secretion from isolated mouse islets by the non-methionine containing antagonist M35. European Journal of Pharmacology, 1993, 232, 35-39.	3.5	27
194	Peptide-Based Matrices as Drug Delivery Vehicles. Current Pharmaceutical Design, 2010, 16, 1167-1178.	1.9	27
195	Insights into the cellular trafficking of splice redirecting oligonucleotides complexed with chemically modified cell-penetrating peptides. Journal of Controlled Release, 2011, 153, 163-172.	9.9	27
196	Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCA7) model. BMC Neuroscience, 2012, 13, 86.	1.9	27
197	Differential regulation of adenylate cyclase activity in rat ventral and dorsal hippocampus by rat galanin. Neuroscience Letters, 1995, 187, 75-78.	2.1	26
198	Inhibition of the bovine papillomavirus E2 protein activity by peptide nucleic acid. Virus Research, 2000, 66, 39-50.	2.2	26

#	Article	IF	Citations
199	Important pharmacophores for binding to galanin receptor 2. Neuropeptides, 2005, 39, 169-171.	2.2	26
200	Inhibition of Autophagy via p53-Mediated Disruption of ULK1 in a SCA7 Polyglutamine Disease Model. Journal of Molecular Neuroscience, 2013, 50, 586-599.	2.3	26
201	Arginine-Rich Cell-Penetrating Peptides Require Nucleolin and Cholesterol-Poor Subdomains for Translocation across Membranes. Bioconjugate Chemistry, 2018, 29, 1168-1177.	3.6	26
202	Tumor gene therapy by systemic delivery of plasmid DNA with cell-penetrating peptides. FASEB BioAdvances, 2019, 1, 105-114.	2.4	26
203	Cell-Penetrating Peptides and Transportan. Pharmaceutics, 2021, 13, 987.	4.5	26
204	Galnon â€“ a low-molecular weight ligand of the galanin receptors. Neuropeptides, 2005, 39, 161-163.	2.2	25
205	Functional Domains of the Mouse Î²3-Adrenoceptor Associated with Differential G Protein Coupling. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 1354-1361.	2.5	25
206	Free uptake of cell-penetrating peptides by fission yeast. FEBS Letters, 2005, 579, 4873-4878.	2.8	25
207	Formulation of Stable and Homogeneous Cell-Penetrating Peptide NF55 Nanoparticles for Efficient Gene Delivery InÂVivo. Molecular Therapy - Nucleic Acids, 2018, 10, 28-35.	5.1	25
208	Cell Penetrating Peptides-Hierarchical Porous Zeolitic Imidazolate Frameworks Nanoparticles: An Efficient Gene Delivery Platform. SSRN Electronic Journal, 0, , .	0.4	25
209	Activation of peripheral galanin receptors: Differential effects on nociception. Pharmacology Biochemistry and Behavior, 2006, 85, 273-280.	2.9	24
210	Comparison of CPP Uptake Methods. Methods in Molecular Biology, 2011, 683, 207-217.	0.9	24
211	Regulation of GTPase and adenylate cyclase activity by amyloid Î²-peptide and its fragments in rat brain tissue. Brain Research, 1999, 850, 179-188.	2.2	23
212	Cholesterol prevents interaction of the cellâ€penetrating peptide transportan with model lipid membranes. Journal of Peptide Science, 2008, 14, 1303-1308.	1.4	23
213	Identification of Cell-Penetrating Peptides That Are Bactericidal to Neisseria meningitidis and Prevent Inflammatory Responses upon Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 3704-3712.	3.2	23
214	Galanin pathogenic mutations in temporal lobe epilepsy. Human Molecular Genetics, 2015, 24, 3082-3091.	2.9	23
215	Role of autophagy in cell-penetrating peptide transfection model. Scientific Reports, 2017, 7, 12635.	3.3	23
216	Pituitary adenylate cyclase activating polypeptide (PACAP) redistributes the blood within the pancreas of anesthetized rats. Regulatory Peptides, 1996, 63, 123-128.	1.9	22

#	Article	IF	Citations
217	Peptitergent PD1 affects the GTPase activity of rat brain cortical membranes. Peptides, 1999, 20, 177-184.	2.4	22
218	Down-regulation of amyloid precursor protein by peptide nucleic acid oligomer in cultured rat primary neurons and astrocytes. Neuroscience Letters, 2003, 336, 55-59.	2.1	22
219	Cell-Penetrating Peptides Delivering siRNAs: An Overview. Methods in Molecular Biology, 2021, 2282, 329-352.	0.9	22
220	Toxicity, Immunogenicity, Uptake, and Kinetics Methods for CPPs. Methods in Molecular Biology, 2015, 1324, 133-148.	0.9	22
221	An update on cell-penetrating peptides with intracellular organelle targeting. Expert Opinion on Drug Delivery, 2022, 19, 133-146.	5.0	22
222	Synthesis of N-protected erythro-phenylalanylepoxides. Tetrahedron: Asymmetry, 1995, 6, 2245-2247.	1.8	21
223	Galanin-Based Peptides, Galparan and Transportan, with Receptor-Dependent and Independent Activities. Annals of the New York Academy of Sciences, 1998, 863, 450-453.	3.8	21
224	Regulation of feeding by galnon. Neuropeptides, 2004, 38, 55-61.	2.2	21
225	Targeting of antisense PNA oligomers to human galanin receptor type 1 mRNA. Neuropeptides, 2004, 38, 316-324.	2.2	21
226	Molecular characterization of the ligand binding site of the human galanin receptor type 2, identifying subtype selective interactions. Journal of Neurochemistry, 2007, 103, 1774-1784.	3.9	21
227	Cell-penetrating peptide secures an efficient endosomal escape of an intact cargo upon a brief photo-induction. Cellular and Molecular Life Sciences, 2013, 70, 4825-4839.	5.4	21
228	Cell-penetrating peptides from cell cultures to in vivo applications. Frontiers in Bioscience - Elite, 2013, E5, 509-516.	1.8	21
229	Peptide-based vectors: recent developments. Biomolecular Concepts, 2014, 5, 479-488.	2.2	21
230	Peptide-Based Delivery of Oligonucleotides Across Bloodâ€“Brain Barrier Model. International Journal of Peptide Research and Therapeutics, 2014, 20, 169-178.	1.9	21
231	Glycosaminoglycans are required for translocation of amphipathic cell-penetrating peptides across membranes. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 1860-1867.	2.6	21
232	Approaches for the discovery of new cell-penetrating peptides. Expert Opinion on Drug Discovery, 2021, 16, 553-565.	5.0	21
233	Cell-Penetrating Mimics of Agonist-Activated G-Protein Coupled Receptors. International Journal of Peptide Research and Therapeutics, 2005, 11, 237-247.	1.9	20
234	Optimized luciferase assay for cell-penetrating peptide-mediated delivery of short oligonucleotides. Analytical Biochemistry, 2015, 484, 136-142.	2.4	20

#	Article	IF	Citations
235	Effective lung-targeted RNAi in mice with peptide-based delivery of nucleic acid. Scientific Reports, 2019, 9, 19926.	3.3	20
236	Studies of cell-penetrating peptides by biophysical methods. Quarterly Reviews of Biophysics, 2022, 55, 1-55.	5.7	20
237	Mimicry of Protein Function with Cell-Penetrating Peptides. Methods in Molecular Biology, 2011, 683, 233-247.	0.9	19
238	Tumour Targeting with Rationally Modified Cell-Penetrating Peptides. International Journal of Peptide Research and Therapeutics, 2012, 18, 361-371.	1.9	19
239	Cell-penetrating peptides as antifungals towards Malassezia sympodialis. Letters in Applied Microbiology, 2012, 54, 39-44.	2.2	19
240	Galanin receptors as a potential target for neurological disease. Expert Opinion on Therapeutic Targets, 2015, 19, 1665-1676.	3.4	19
241	Effects of Three Galanin Analogs on the Outward Current Evoked by Galanin in Locus Coeruleus a. Annals of the New York Academy of Sciences, 1998, 863, 459-465.	3.8	18
242	Intracerebroventricular administration of galanin decreases free water intake and operant water reinforcer efficacy in water-restricted rats. Neuropeptides, 2005, 39, 117-124.	2.2	18
243	Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides. Therapeutic Delivery, 2011, 2, 71-82.	2.2	18
244	Novel Galanin Receptor Subtype Specific Ligand in Depression Like Behavior. Neurochemical Research, 2013, 38, 398-404.	3.3	18
245	Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides. Nucleic Acid Therapeutics, 2015, 25, 65-77.	3.6	18
246	Cell-Penetrating Peptides. Methods in Molecular Biology, 2015, 1324, v-viii.	0.9	18
247	Ala 5 -galanin (2â€“11) is a GAL 2 R specific galanin analogue. Neuropeptides, 2016, 60, 75-82.	2.2	18
248	Amyloid-like Self-Assembly of a Hydrophobic Cell-Penetrating Peptide and Its Use as a Carrier for Nucleic Acids. ACS Applied Bio Materials, 2021, 4, 6404-6416.	4.6	18
249	Application of PepFect Peptides for the Delivery of Splice-Correcting Oligonucleotides. Methods in Molecular Biology, 2011, 683, 361-373.	0.9	18
250	Differential Regulation of GTPase Activity by Mastoparan and Galparan. Archives of Biochemistry and Biophysics, 1998, 349, 321-328.	3.0	17
251	Effects of galnon, a non-peptide galanin-receptor agonist, on insulin release from rat pancreatic islets. Biochemical and Biophysical Research Communications, 2005, 328, 213-220.	2.1	17
252	Binding of Chimeric Peptides M617 and M871 to Galanin Receptor Type 3 Reveals Characteristics of Galanin Receptorâ€“Ligand Interaction. International Journal of Peptide Research and Therapeutics, 2010, 16, 17-22.	1.9	17

#	Article	IF	Citations
253	Intracellular Delivery of Short Interfering RNA in Rat Organ of Corti Using a Cell-penetrating Peptide PepFect6. Molecular Therapy - Nucleic Acids, 2012, 1, e61.	5.1	17
254	Targeting prion propagation using peptide constructs with signal sequence motifs. Archives of Biochemistry and Biophysics, 2014, 564, 254-261.	3.0	17
255	The role of endocytosis in the uptake and intracellular trafficking of PepFect14â€“nucleic acid nanocomplexes via class A scavenger receptors. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 3205-3216.	2.6	17
256	Combination with antimicrobial peptide lyses improves loop-mediated isothermal amplification based method for Chlamydia trachomatis detection directly in urine sample. BMC Infectious Diseases, 2016, 16, 329.	2.9	17
257	Methods to follow intracellular trafficking of cell-penetrating peptides. Journal of Drug Targeting, 2016, 24, 508-519.	4.4	17
258	Targeting cytokine expression in glial cells by cellular delivery of an NF-ÎºB decoy. Journal of Molecular Neuroscience, 2007, 31, 209-219.	2.3	17
259	Effects of vasopressinâ€“mastoparan chimeric peptides on insulin release and G-protein activity. Regulatory Peptides, 1999, 82, 45-51.	1.9	16
260	Assessment of new functional roles for galanin in the CNS. Neuropeptides, 2005, 39, 323-326.	2.2	16
261	Uptake Mechanisms of Cell-Penetrating Peptides Derived from the Alzheimerâ€™s Disease Associated Gamma-Secretase Complex. International Journal of Peptide Research and Therapeutics, 2006, 12, 105-114.	1.9	16
262	Relevance of the N-terminal NLS-like sequence of the prion protein for membrane perturbation effects. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 206-213.	2.6	16
263	Effect of a Fusion Peptide by Covalent Conjugation of a Mitochondrial Cell-Penetrating Peptide and a Glutathione Analog Peptide. Molecular Therapy - Methods and Clinical Development, 2017, 5, 221-231.	4.1	16
264	Intracellular delivery of therapeutic antisense oligonucleotides targeting mRNA coding mitochondrial proteins by cell-penetrating peptides. Journal of Materials Chemistry B, 2020, 8, 10825-10836.	5.8	16
265	Cell-Penetrating Peptide and siRNA-Mediated Therapeutic Effects on Endometriosis and Cancer In Vitro Models. Pharmaceutics, 2021, 13, 1618.	4.5	16
266	A study of melittin, motilin and galanin in reversed micellar environments, using circular dichroism spectroscopy. Biophysical Chemistry, 1996, 59, 185-192.	2.8	15
267	Cell-Penetrating Peptides. Methods in Molecular Biology, 2022, 2383, 3-32.	0.9	15
268	A study of the interaction of some neuropeptides and their analogs with bilayer lipid membranes and liposomes. Bioelectrochemistry, 1997, 42, 123-132.	1.0	14
269	Cellular Delivery of Peptide Nucleic Acid by Cell-Penetrating Peptides. , 2005, 298, 131-141.		14
270	Intracellular Target-Specific Accretion of Cell Penetrating Peptides and Bioportides: Ultrastructural and Biological Correlates. Bioconjugate Chemistry, 2016, 27, 121-129.	3.6	14

#	Article	IF	Citations
271	Simultaneous membrane interaction of amphipathic peptide monomers, self-aggregates and cargo complexes detected by fluorescence correlation spectroscopy. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 491-504.	2.6	14
272	Expression of galanin receptor-1 (GALR1) in the rat trigeminal ganglia and molar teeth. Neuroscience Research, 2002, 42, 197-207.	1.9	13
273	Novel Mastoparan Analogs Induce Differential Secretion from Mast Cells. Chemistry and Biology, 2002, 9, 63-70.	6.0	13
274	Determining receptorâ€“ligand interaction of human galanin receptor type 3. Neurochemistry International, 2010, 57, 804-811.	3.8	13
275	Peptide Nanoparticles for Oligonucleotide Delivery. Progress in Molecular Biology and Translational Science, 2011, 104, 397-426.	1.7	13
276	Dendritic Glutamate Receptor mRNAs Show Contingent Local Hotspot-Dependent Translational Dynamics. Cell Reports, 2013, 5, 114-125.	6.4	13
277	Comparison of Peptide- and Lipid-Based Delivery of miR-34a-5p Mimic into PPC-1 Cells. Nucleic Acid Therapeutics, 2017, 27, 295-302.	3.6	13
278	Mutagenesis Study on Human Galanin Receptor GalR1 Reveals Domains Involved in Ligand Binding a. Annals of the New York Academy of Sciences, 1998, 863, 78-85.	3.8	12
279	Synthesis of Cell-Penetrating Peptides for Cargo Delivery. , 2005, 298, 77-89.		12
280	Novel Fatty Acid Modifications of Transportan 10. International Journal of Peptide Research and Therapeutics, 2010, 16, 247-255.	1.9	12
281	Peptide-Ligand Binding Modeling of siRNA with Cell-Penetrating Peptides. BioMed Research International, 2014, 2014, 1-7.	1.9	12
282	The effect of main urine inhibitors on the activity of different DNA polymerases in loop-mediated isothermal amplification. Expert Review of Molecular Diagnostics, 2017, 17, 403-410.	3.1	12
283	Functional effects and ligand binding of chimeric galaninâ€neuropeptide Y (NPY) peptides on NPY and galanin receptor types. British Journal of Pharmacology, 1994, 111, 1129-1134.	5.4	11
284	Attempt to Solubilize Na+/K+-Exchanging ATPase with Amphiphilic Peptide PD1.. Acta Chemica Scandinavica, 1997, 51, 403-406.	0.7	11
285	Synthesis of Cell-Penetrating Peptide-PNA Constructs. , 2002, 208, 225-236.		10
286	Co-transduction of Sleeping Beauty Transposase and Donor Plasmid via a Cell-penetrating Peptide: A simple one step Method. International Journal of Peptide Research and Therapeutics, 2008, 14, 58-63.	1.9	10
287	Lâ€Alaâ€substituted rat galanin analogs distinguish between hypothalamic and jejunal galanin receptor subtypes. Chemical Biology and Drug Design, 1997, 49, 195-200.	1.1	10
288	GABAergic Terminals Are a Source of Galanin to Modulate Cholinergic Neuron Development in the Neonatal Forebrain. Cerebral Cortex, 2014, 24, 3277-3288.	2.9	10

#	Article	IF	Citations
289	Application of CPPs for Brain Delivery. Methods in Molecular Biology, 2015, 1324, 349-356.	0.9	10
290	Amyloid precursor protein carboxy-terminal fragments modulate G-proteins and adenylate cyclase activity in Alzheimerâ€™s disease brain. Molecular Brain Research, 2003, 117, 73-82.	2.3	9
291	Manual Solid Phase Synthesis of Glutathione Analogs. , 2005, 298, 241-257.		9
292	Novel viral vectors utilizing intron splice-switching to activate genome rescue, expression and replication in targeted cells. Virology Journal, 2011, 8, 243.	3.4	9
293	Development of a novel nanoparticle by dual modification with the pluripotential cellâ€penetrating peptide PepFect6 for cellular uptake, endosomal escape, and decondensation of an siRNA core complex. Biopolymers, 2013, 100, 698-704.	2.4	9
294	Central Administration of Galanin Receptor 1 Agonist Boosted Insulin Sensitivity in Adipose Cells of Diabetic Rats. Journal of Diabetes Research, 2016, 2016, 1-9.	2.3	9
295	PAIR Technology: Exon-Specific RNA-Binding Protein Isolation in Live Cells. Methods in Molecular Biology, 2011, 683, 473-486.	0.9	9
296	Solvent stabilized solution structures of galanin and galanin analogs, studied by circular dichroism spectroscopy. Biochimica Et Biophysica Acta - Biomembranes, 1995, 1236, 259-265.	2.6	8
297	An improved synthesis of releasable luciferinâ€“CPP conjugates. Tetrahedron Letters, 2009, 50, 4731-4733.	1.4	8
298	Galanin, through GalR1 but not GalR2 receptors, decreases motivation at times of high appetitive behavior. Behavioural Brain Research, 2013, 239, 90-93.	2.2	8
299	<scp>PDGF</scp> beta targeting in cervical cancer cells suggest a fineâ€tuning of compensatory signalling pathways to sustain tumourigenic stimulation. Journal of Cellular and Molecular Medicine, 2015, 19, 371-382.	3.6	8
300	Astrocytes promote ethanol-induced enhancement of intracellular Ca2+ signals through intercellular communication with neurons. IScience, 2021, 24, 102436.	4.1	8
301	Analogs of Galanin(1--16) Modified in Positions 1--3 as Ligands to Rat Hypothalamic Galanin Receptors.. Acta Chemica Scandinavica, 1994, 48, 434-438.	0.7	8
302	The structure of the rodent and porcine neuropeptide galanin and antagonists as determined by FTIR and CD spectroscopy. Canadian Journal of Chemistry, 1994, 72, 1495-1499.	1.1	7
303	Characterisation of a new chimeric ligand for galanin receptors: galanin(1â€“13)-[d-Trp32]-neuropeptide Y(25â€“36)amide. Regulatory Peptides, 2001, 102, 15-19.	1.9	7
304	Intracerebroventricularly administered galanin does not alter operant reaction time or differentially reinforced high rate schedule operant responding in rats. Neuroscience Letters, 2004, 369, 245-249.	2.1	7
305	Modulating Anti-MicroRNA-21 Activity and Specificity Using Oligonucleotide Derivatives and Length Optimization. ISRN Pharmaceutics, 2012, 2012, 1-7.	1.0	7
306	Transfection of Infectious RNA and DNA/RNA Layered Vectors of Semliki Forest Virus by the Cell-Penetrating Peptide Based Reagent PepFect6. PLoS ONE, 2013, 8, e69659.	2.5	7

#	Article	IF	Citations
307	CPP-Based Delivery System for In Vivo Gene Delivery. Methods in Molecular Biology, 2015, 1324, 339-347.	0.9	7
308	Refinement of a Quantitative Structureâ€“Activity Relationship Model for Prediction of Cell-Penetrating Peptide Based Transfection Systems. International Journal of Peptide Research and Therapeutics, 2017, 23, 91-100.	1.9	7
309	Cell-Penetrating Peptides-Based Strategies for the Delivery of Splice Redirecting Antisense Oligonucleotides. Methods in Molecular Biology, 2011, 764, 75-89.	0.9	7
310	Improvement of Transfection with PepFects Using Organic and Inorganic Materials. Methods in Molecular Biology, 2022, 2383, 555-567.	0.9	7
311	Comparison of the solution structures of the chimeric peptides galanin(1-12)-Ala-neuropeptide Y(25-36)amide and galanin(1-12)-Pro-neuropeptide Y(25-36)amide. FEBS Journal, 1994, 222, 573-581.	0.2	6
312	Ligand binding and functional effects of systematic double d-amino acid residue substituted neuropeptide Y analogs on Y1 and Y2 receptor types. Regulatory Peptides, 1996, 62, 131-136.	1.9	6
313	Galparan induces in vivo acetylcholine release in the frontal cortex. Brain Research, 1997, 756, 174-178.	2.2	6
314	Toxicity Methods for CPPs. Methods in Molecular Biology, 2011, 683, 195-205.	0.9	6
315	Human Protein 53-Derived Cell-Penetrating Peptides. International Journal of Peptide Research and Therapeutics, 2012, 18, 291-297.	1.9	6
316	SCARA Involvement in the Uptake of Nanoparticles Formed by Cell-Penetrating Peptides. Methods in Molecular Biology, 2015, 1324, 163-174.	0.9	6
317	Pharmacological stimulation of GAL1R but not GAL2R attenuates kainic acid-induced neuronal cell death in the rat hippocampus. Neuropeptides, 2016, 58, 83-92.	2.2	6
318	Transcriptional Profiling Reveals Ribosome Biogenesis, Microtubule Dynamics and Expression of Specific lncRNAs to be Part of a Common Response to Cell-Penetrating Peptides. Biomolecules, 2020, 10, 1567.	4.0	6
319	Role of cysteine 341 and arginine 348 of GLP-1 receptor in G-protein coupling. Molecular Biology Reports, 2007, 34, 53-60.	2.3	5
320	A High-Throughput Kinetic Assay for RNA-Cleaving Deoxyribozymes. PLoS ONE, 2015, 10, e0135984.	2.5	5
321	Novel Efficient Cell-Penetrating, Peptide-Mediated Strategy for Enhancing Telomerase Inhibitor Oligonucleotides. Nucleic Acid Therapeutics, 2015, 25, 306-310.	3.6	5
322	Galanin receptor ligands. SpringerPlus, 2015, 4, L18.	1.2	5
323	Calcium-mobilizing actions of chimeric hormone-mastoparan peptides. Biochemical Society Transactions, 1997, 25, 450S-450S.	3.4	4
324	Classes and Applications of Cell-Penetrating Peptides. , 2019, , 29-82.		4

#	Article	IF	Citations
325	Effect of small molecule signaling in PepFect14 transfection. PLoS ONE, 2020, 15, e0228189.	2.5	4
326	Mapping of Protein Transduction Pathways with Fluorescent Microscopy. Methods in Molecular Biology, 2011, 683, 165-179.	0.9	4
327	CRISPR/Cas9 Plasmid Delivery Through the CPP: PepFect14. Methods in Molecular Biology, 2022, 2383, 587-593.	0.9	4
328	Mimicry of Dopamine 1 Receptor Signaling with Cell-Penetrating Peptides. International Journal of Peptide Research and Therapeutics, 2021, 27, 83-90.	1.9	3
329	Cell-Penetrating Peptides Predicted From CASC3, AKIP1, and AHRR Proteins. Frontiers in Pharmacology, 2021, 12, 716226.	3.5	3
330	The Internalization Mechanisms and Bioactivity of the Cell-Penetrating Peptides. , 0, , 125-143.		3
331	PepFect6 Mediated SiRNA Delivery into Organotypic Cultures. Methods in Molecular Biology, 2016, 1364, 27-35.	0.9	3
332	Characterization of Cellular Internalization Pathways for CPP-Mediated Oligonucleotide Delivery. Methods in Molecular Biology, 2011, 683, 219-230.	0.9	3
333	Quantitative Microplate Assay for Real-Time Nuclease Kinetics. PLoS ONE, 2016, 11, e0154099.	2.5	3
334	Endpoint and Kinetic Approaches for Assessing Transfection Efficacy in Mammalian Cell Culture. Methods in Molecular Biology, 2022, 2383, 529-545.	0.9	3
335	Galanin and perseveration. Brain Research, 2005, 1041, 143-148.	2.2	2
336	Cell-Penetrating Peptides Targeting Mitochondria. , 2018, , 593-611.		2
337	Cell-Translocation Mechanisms of CPPs. , 2019, , 359-394.		2
338	Methods for CPP Functionalization. , 2019, , 83-156.		2
339	PepFect14 Signaling and Transfection. Methods in Molecular Biology, 2022, 2383, 229-246.	0.9	2
340	Transfection of Heat Shock Protein 70ÂkDa (HSP70). International Journal of Peptide Research and Therapeutics, 2022, 28, .	1.9	2
341	Distribution of CPP-Protein Complexes in Freshly Resected Human Tissue Material. Pharmaceuticals, 2010, 3, 621-635.	3.8	1
342	Implementation of antimicrobial peptides for sample preparation prior to nucleic acid amplification in point-of-care settings. Expert Review of Molecular Diagnostics, 2017, 17, 1117-1125.	3.1	1

#	Article	IF	Citations
343	Therapeutic Potential of CPPs. , 2019, , 409-461.		1
344	Targeting Strategies. , 2019, , 195-263.		1
345	Design and Synthesis of a Peptide-Based Glioma-Targeted Drug Delivery Vector gHope2. Methods in Molecular Biology, 2021, 2355, 117-129.	0.9	1
346	Synthesis of NickFects, a New Family of CPPs, by Solid-Phase Peptide Synthesis. Methods in Molecular Biology, 2020, 2103, 239-247.	0.9	1
347	Co-localized neuropeptide Y and GABA have complementary presynaptic effects on sensory synaptic transmission. European Journal of Neuroscience, 1998, 10, 2856-2870.	2.6	1
348	Twenty-Five Years of Galanin Research. , 2009, , 237-260.		1
349	Tissue Analysis of Lung-Targeted Delivery of siRNA and Plasmid DNA. Methods in Molecular Biology, 2022, 2383, 547-553.	0.9	1
350	Cell-Penetrating Peptide-Mediated Delivery of Peptide Nucleic Acid (PNA) Oligomers. Cold Spring Harbor Protocols, 2008, 2008, pdb.prot4889.	0.3	0
351	Protein Delivery and Mimicry. , 2019, , 157-193.		0
352	Clinical Trials and Commercialization Using CPPs. , 2019, , 395-408.		0
353	Methods for Structural Studies of CPPs. , 2019, , 289-323.		0
354	Kinetics of CPPs Cellular Uptake. , 2019, , 325-337.		0
355	Toxicity and Immune Response. , 2019, , 339-357.		0
356	Chimeric Mastoparans: Biological Probes and Designer Secretagogues. , 2001, , 750-751.		0
357	Methods for Detection and Visualization of CPPs. , 2019, , 265-288.		0
358	Intracellular third loop of galanin receptor as G-protein interaction site. , 2002, , 662-663.		0
359	Utilization of Cell-Penetrating Peptides for In Vivo Delivery of Bioactive Cargo: The Effect of Nanoparticle Formulation. Methods in Molecular Biology, 2022, 2383, 247-253.	0.9	0
360	Mitochondrial Targeting Probes, Drug Conjugates, and Gene Therapeutics. Methods in Molecular Biology, 2022, 2383, 429-446.	0.9	0